-- 
Israel Stocks: Delek Automotive, RadVision, D-Pharm, Bioline

-- B y   S u s a n   L e r n e r
-- 
2011-07-05T16:03:02Z

-- http://www.bloomberg.com/news/2011-07-05/israel-stocks-delek-automotive-radvision-d-pharm-bioline.html
Israel’s TA-25 Index dropped for a
second day, slipping less than 0.1 percent to 1,248.34 at 1:11
p.m. in Tel Aviv. Investors traded about 1.07 billion shekels
($314 million) in shares and convertible securities.  The following stocks rose or fell today. Symbols are in
parentheses.  Bioline RX Ltd. (BLRX)   jumped to the highest level since
May 15, climbing 1.8 percent to 1.916 shekels. The
biopharmaceutical company said it plans to list its shares on
the Nasdaq.  BluePhoenix Solutions Ltd. (BPHX)   advanced to the
highest level in a month, gaining 2.2 percent to 4.118 shekels.
The  software company  extended a $1 million contract from a
Chinese financial institution.  Delek Automotive Systems Ltd. (DLEA)   slid the most since
Sept. 16, dropping 3.9 percent to 36.61 shekels. Psagot
Investment House Ltd. cut its share-price estimate for the
importer of Mazda cars to 42.7 shekels from 45.9 shekels.  D. Medical Industries Ltd. (DMED IT) climbed to the highest
since June 1, increasing 4.6 percent to 12.82 shekels. The
developer of drug-delivery devices’ Spring Health Solutions Ltd.
unit signed a preliminary agreement for the distribution of its
infusion sets in  Canada .  D-Pharm Ltd. (DPRM)   retreated 3.3 percent to 12.64
shekels, the lowest since the shares began trading in August
2009. The biopharmaceutical company’s board authorized raising
funds through a rights offering to existing shareholders.  Pilat Media Global Plc (PGB)   increased the most since
Oct. 10, jumping 7.4 percent to 2.152 shekels. The developer of
business-management software said Sintec Media Ltd. increased
its holding in the company to 21.48 percent.  RadVision Ltd. (RVSN)   tumbled to the lowest since Oct.
27, sliding 7.7 percent to 24.62 shekels. The maker of video-
conferencing systems reduced its second-quarter outlook,
widening its adjusted loss estimate to 27 cents to 30 cents a
share from 12 cents and lowering its revenue forecast to $18
million to $18.5 million from $22 million.  To contact the reporter on this story:
 Susan Lerner  in Jerusalem at 
 Slerner2@bloomberg.net .  To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  